Scribe Therapeutics Inc.: 5%+ holders

As of November 7, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Scribe Therapeutics Inc. The largest reported stake is Avoro Capital Advisors LLC's, at 16.37%. 4 filings are on record since July 29, 2026 (Schedule 13D, July 30, 2026).

Who owns Scribe Therapeutics, Inc.?

ELI LILLY & Co also filed stake reports on 5 other companies ↓

Sell to companies like Scribe Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-03 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 1,802,178 · Sole dispositive: 0 · Shared dispositive: 1,802,178 · SCHEDULE 13G, 2026-08-03
• Filing 2026-07-30 · Reporting person: Avoro Capital Advisors LLC · Sole voting: 0 · Shared voting: 2,598,973 · Sole dispositive: 0 · Shared dispositive: 2,598,973 · SCHEDULE 13D, 2026-07-30
• Filing 2026-07-30 · Reporting person: ELI LILLY & Co · Sole voting: 1,388,161 · Shared voting: 0 · Sole dispositive: 1,388,161 · Shared dispositive: 0 · SCHEDULE 13D, 2026-07-30
• Filing 2026-07-29 · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 1,348,825 · Sole dispositive: 0 · Shared dispositive: 1,348,825 · SCHEDULE 13D, 2026-07-29

Scribe Therapeutics Inc. has 4 Schedule 13D or 13G filings on record since 2026-07-29. 4 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Scribe Therapeutics Inc. and the warning signs.

See Scribe Therapeutics Inc.'s free Snapshot Watch Scribe Therapeutics Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Scribe Therapeutics Inc. and the records around it.

Scribe Therapeutics Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• ELI LILLY & Co also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Ionetix Corp / DE / (Jul 2026), ProQR Therapeutics N.V. (Jul 2026)
• Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
• ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)

Want the whole picture on Scribe Therapeutics Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Scribe Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Scribe Therapeutics Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   8 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Scribe Therapeutics Inc. by CUSIP 811033109 and gives its principal executive office as 1150 Marina Village Parkway, Alameda, CA 94501 (SCHEDULE 13G, 2026-08-03).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-08-03

Source of funds (Item 3)

Of the 3,088,888 shares of Common Stock reported herein, 697,650 shares, consisting of 474,402 shares held directly by Avoro Life Sciences and 223,248 shares held directly by Avoro Ventures Fund, were issued upon the automatic conversion of the Funds' shares of the Issuer's Series B Preferred Stock at the closing of the Issuer's initial public offering ("IPO") on July 27, 2026, each share of Series B Preferred Stock having converted into Common Stock on a one-for-0.1689 basis without the payment of any additional consideration.Avoro Capital Advisors LLC, SCHEDULE 13D, 2026-07-30

The Reporting Person beneficially owns an aggregate of 1,388,161 shares of Common Stock of the Issuer, consisting of (a) 1,054,828 shares of Common Stock that were issued on July 10, 2026 to the Reporting Person upon conversion of the Issuer's 8% Convertible Promissory Note ("Promissory Note") previously acquired for an aggregate purchase price of $30.0 million; and (b) 333,333 shares of Common Stock purchased by the Reporting Person in the IPO at the public offering price of $15.00 per share, for an aggregate purchase price of approximately $5.0 million.ELI LILLY & Co, SCHEDULE 13D, 2026-07-30

In July 2026, OrbiMed Advisors and GP VIII, pursuant to their authority under the limited partnership agreement of OrbiMed Private Investments VIII, LP ("OPI VIII"), as more particularly described in Item 6 below, caused OPI VIII to purchase 2,065,672 shares of Series B preferred stock, par value $0.001 per share of the Issuer ("Series B preferred stock"). Each outstanding share of Series B preferred stock converted into Shares at a ratio of 1-for-0.1689 immediately upon the completion of the Issuer's initial public offering (the "IPO").Orbimed Advisors LLC, SCHEDULE 13D, 2026-07-29

Purpose of Transaction (Item 4)

Orbimed Advisors LLC

This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-29; the filing has the rest

ELI LILLY & Co

The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis. Except as set forth herein, the Reporting Person does not currently have any specific plan or proposal to acquire or dispose of Common Stock of the Issuer or any securities exercisable for or convertible into Common Stock of the Issuer, but the Reporting Person, consistent with its investment purpose, may at any time and from time to time directly or indirectly acquire additional or all shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer, or dispose of any or all of its shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer. The Reporting Person's determination to make any such acquisitions or dispositions, in each such case, will depend upon a variety of factors, including, but not limited to, an ongoing evaluation of its investment in such securities, applicable legal and/or contractual restrictions, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Person and/or other investment considerations. In addition, in connection with the foregoing, the Reporting Person may engage in hedging or other transactions with respect to securities of the Issuer, including but not limited to, swaps and other …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-30; the filing has the rest

Avoro Capital Advisors LLC

The Reporting Persons acquired the shares of Common Stock reported herein for investment purposes. Dr. Aghazadeh serves as a member of the board of directors of the Issuer. The Issuer and certain of its stockholders, including Avoro Life Sciences and Avoro Ventures Fund, are parties to the Amended and Restated Investors' Rights Agreement, dated March 17, 2021, among the Issuer and certain of its stockholders (the "IRA"). Pursuant to the IRA, holders of Registrable Securities (as defined in the IRA), including the Funds, are entitled to certain registration rights with respect to shares of Common Stock issued upon conversion of the Issuer's preferred stock, with such rights terminating upon the earliest to occur of (i) the closing of a Deemed Liquidation Event (as defined in the IRA), (ii) such time as Rule 144 under the Securities Act of 1933, as amended, is available for the sale of all of a holder's shares without limitation during a three-month period without registration and (iii) the third anniversary of the closing of the IPO. The IRA also contains customary lock-up provisions pursuant to which the Funds have agreed not to sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of, any Common Stock or other securities of the Issuer held immediately prior to the effective date of the registration statement IPO for a period of 180 days following …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-30; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Scribe Therapeutics Inc.

Who owns Scribe Therapeutics Inc.?

On this page, 4 holders' latest ownership filings report 5% or more of Scribe Therapeutics Inc.: Avoro Capital Advisors LLC (16.37%, Schedule 13D, filed 2026-07-30), RA Capital Management, L.P. (9.6%, Schedule 13G, filed 2026-08-03), ELI LILLY & Co (7.3%, Schedule 13D, filed 2026-07-30) and Orbimed Advisors LLC (7.2%, Schedule 13D, filed 2026-07-29).

Who are the largest shareholders of Scribe Therapeutics Inc.?

By the share each holder's latest filing reports, the largest holders of Scribe Therapeutics Inc. on this page are Avoro Capital Advisors LLC (16.37%), RA Capital Management, L.P. (9.6%) and ELI LILLY & Co (7.3%).

When did Avoro Capital Advisors LLC buy into Scribe Therapeutics Inc.?

The filings give report dates, not purchase dates. The earliest filing from Avoro Capital Advisors LLC on this page is the Schedule 13D, filed 2026-07-30, reporting 16.37%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Scribe Therapeutics Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Scribe Therapeutics Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Scribe Therapeutics Inc. is mentioned again
• Find former Scribe Therapeutics Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes